# A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

> **NCT05891496** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 23 (actual)

## Conditions studied

- Alzheimers Disease

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05891496
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-20
- **Primary completion:** 2024-08-19
- **Final completion:** 2025-09-08
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891496, "A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease". Retrieved via AI Analytics 2026-08-10 from https://api.ai-analytics.org/clinical/NCT05891496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*